Skip to main content
  • Clinical Trials
  • SPRinstitute™ Library
Menu
Home
SPR
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us

News

Breadcrumb

  1. Home
  2. News

All News

▼
Pain Medicine News 2023 Pain Medicine News 2023

Minimally invasive PNS may be an important part of step-up approach to groin pain treatment

Research, data + publications
women-of-influence_blog-1200x900_v1.jpg women-of-influence_blog-1200x900_v1.jpg

Maria Bennett, President, CEO, and Founder, highlighted as Woman of Influence

Company news
VeteransBlogPostImage_v1.png VeteransBlogPostImage_v1.png

What does Veterans Day mean to you?

Team + culture
shoulder blog post 2023 shoulder blog post 2023

A drug-free treatment for shoulder pain

Perspectives from health care professionals
Sheth head and neck pain blog post 2023 Sheth head and neck pain blog post 2023

Dr. Samir Sheth discusses how the SPRINT® PNS System has impacted his approach to treating patients with chronic head and neck pain

Perspectives from health care professionals
breast cancer awarenss with Dr. Gulati breast cancer awarenss with Dr. Gulati

A discussion on pain management options for patients with breast cancer with Dr. Amitabh Gulati

Perspectives from health care professionals
Maria Bennett EY Entrepreneur Maria Bennett EY Entrepreneur

Maria Bennett, SPR CEO and Founder, recognized by Ernst & Young Entrepreneur of the Year program

Company news
Unknown-12-1.jpeg Unknown-12-1.jpeg

5,000th SPRINT PNS System patient marks significant milestone in PNS adoption

Company news
Josh Boggs, CSO Josh Boggs, CSO

SPR appoints Josh Boggs, PhD, as Chief Scientific Officer

Company news
CRPS title image CRPS title image

Understanding complex regional pain syndrome (CRPS)

Patient education
SPR Pain Continuum for blog SPR Pain Continuum for blog

Tips for incorporating SPRINT PNS into your pain care continuum

Perspectives from health care professionals
physician with patient physician with patient

How to prepare for an appointment with a pain physician

Patient education

Pagination

  • Previous page ‹
  • Page1
  • Page2
  • Current page3
  • Page4
  • Next page ›
  • Healthcare Professionals
    • SPRINT® PNS System
      • Overview
      • Product Details
    • Clinical Evidence
    • Video Resources
    • Reimbursement
    • Education
    • Safety Information
    • MRI Safety Information
  • Patients & Caregivers
    • SPRINT® PNS System
      • Why SPRINT?
      • How It Works
      • What To Expect
      • Helpful FAQs
      • Safety Information
      • MRI Safety Information
    • Resources
      • Overview
      • Instructional Videos
      • Patient Stories
      • Recursos para pacientes
      • Clinical Evidence
  • About Us
    • About SPR
    • Leadership
    • Company Credo
  • News
  • Events
  • Careers
    • Overview
    • Job Listing
  • Contact Us
  • Compliance
  • Consumer Health Data Request Form
  • CPRA Requests
  • FCOI Policy
  • Indications for Use
  • MRI Safety Information
  • Patent Information
  • Product Terms and Conditions
  • Safety Information
  • Trademarks
  • Billing Portal
Home
  • Consumer Health Data and Information Privacy Policy
  • Terms of Use
Visit us on Facebook
Visit us on Twitter
Visit us on Instagram
Visit us on YouTube
Visit us on LinkedIn

The SPRINT Peripheral Nerve Stimulation (PNS) System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. It is intended to be implanted for up to 60 days and provide sustained pain relief for up to 3 months after the end of treatment. The SPRINT PNS System is not intended to be placed in the region innervated by the cranial and facial nerves. Refer to Indications for Use for the SPRINT System’s additional indication referencing acute pain. 

Physicians should use their best judgment when deciding when to use the SPRINT PNS System. For more information see the SPRINT PNS System IFU. Most common adverse events are skin irritation and erythema. Results may vary. Rx only.

View references for support of all claims.

Product and brand names/logos are registered or common law trademarks of SPR.

© 2026 SPR. All Rights Reserved.